Ftse Mib
33.986,90
1,06%
DAX
18.175,21
1,01%
S&P 500
5.180,74
1,03%
NASDAQ
16.349,25
1,19%
Bitcoin
63.798,36
1,00%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Astria Therapeutics Inc (ATXS) Astria Therapeutics Inc (ATXS) Notizie

Astria Therapeutics Inc

ATXS
9,77
0,22 (2,30%)
07 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
02/5/202422:00BWAstria Therapeutics Announces Inducement Grants Under Nasdaq..
09/4/202414:00BWAstria Therapeutics Appoints Sunil Agarwal to Its Board of..
03/4/202422:10BWAstria Therapeutics Announces Inducement Grants Under Nasdaq..
25/3/202412:30BWAstria Therapeutics Announces Positive Initial..
05/3/202422:10BWAstria Therapeutics Announces Inducement Grants Under Nasdaq..
04/3/202423:22EDGAR2Form 8-K - Current report
04/3/202423:20EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
04/3/202422:10BWAstria Therapeutics Reports Fourth Quarter and Full Year..
04/3/202422:02EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
20/2/202414:00BWAstria Therapeutics to Present at Upcoming American Academy..
14/2/202421:48EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202421:00EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202414:36EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
12/2/202422:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202422:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202414:00BWAstria Therapeutics to Present at Upcoming Oppenheimer 34th..
05/2/202422:00BWAstria Therapeutics Announces Inducement Grants Under Nasdaq..
31/1/202415:00EDGAR2Form 8-K - Current report
31/1/202414:59EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
30/1/202423:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/1/202415:08BWAstria Therapeutics Announces Pricing of $125 Million..
30/1/202412:01EDGAR2Form 8-K - Current report
29/1/202422:39EDGAR2Form 144 - Report of proposed sale of securities
16/1/202422:18EDGAR2Form SC 13G - Statement of acquisition of beneficial..
05/1/202414:30EDGAR2Form 8-K - Current report
02/1/202422:16EDGAR2Form SC 13G - Statement of acquisition of beneficial..
02/1/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
28/12/202320:09EDGAR2Form S-3/A - Registration statement under Securities Act of..
20/12/202322:30EDGAR2Form 8-K - Current report
15/12/202314:30EDGAR2Form S-3 - Registration statement under Securities Act of..
04/12/202322:00BWAstria Therapeutics Announces Inducement Grants Under Nasdaq..
27/11/202314:00BWAstria Therapeutics to Present STAR-0215 Data at the 2023..
21/11/202314:00BWAstria Therapeutics to Present at Upcoming 6th Annual..
13/11/202322:02EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/11/202314:06EDGAR2Form 8-K - Current report
13/11/202314:00BWAstria Therapeutics Reports Third Quarter Financial Results..
10/11/202314:00BWAstria Therapeutics Presents New Phase 1a Data Confirming..
09/11/202314:00BWAstria Therapeutics to Present at Upcoming Jefferies London..
03/11/202313:10BWAstria Therapeutics to Present New STAR-0215 Data at the..
02/11/202321:00BWAstria Therapeutics Announces Inducement Grants Under Nasdaq..
30/10/202313:00BWAstria Therapeutics to Report Third Quarter 2023 Financial..
12/10/202323:04EDGAR2Form 8-K - Current report
12/10/202323:01EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
12/10/202314:00EDGAR2Form 8-K - Current report
12/10/202301:14BWAstria Therapeutics Announces Pricing of $64 Million..
11/10/202323:14EDGAR2Form 8-K - Current report
Apertura: 9,62 Min: 9,545 Max: 9,83
Chiusura: 9,55

La tua Cronologia

NASDAQ
ATXS
Astria Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network